HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Viread (Tenofovir)

The Basics | News | Research | Tenofovir for HIV Prevention

Show Archived (Historical) Articles

Brand Name:	Viread
Generic Name:	Tenofovir disoproxil fumarate, TDF
Adult Single Dose:	One 300-mg tablet (once a day)
Food & Liquid Restrictions:	None
Drug Class:	NRTI

The Basics

An Overview of Viread (Tenofovir) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
Tenofovir (Viread) (August 23, 2009)
To read PDF, click here
From AIDS InfoNet
Viread (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Patient Information About Viread (Tenofovir) (PDF) (November 2008)
From Gilead Sciences, Inc.
Viread (Tenofovir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
Tenofovir (Viread) (August 15, 2006)
From AIDS Treatment Data Network

News

FDA Approves Gilead's Antiretroviral Viread for Use as Hepatitis B Treatment (August 13, 2008)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Gilead Sciences May Lose Patent for Viread (January 25, 2008)
Looser patent laws could mean generic version of Tenofovir to come.
In Housing Works AIDS Issues Update, from Housing Works
U.S. Patent Agency to Review Gilead's Claim on Tenofovir (July 20, 2007)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration
Drug Development News: Fixed-Dose Combinations (May/June 2004)
The Food and Drug Administration's fast-track approval process for fixed-dose combinations is about to bear fruit.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
To read PDF, click here
From U.S. Food and Drug Administration
Atazanavir/Tenofovir Combo Should Be Boosted With Ritonavir (August 8, 2003)
From U.S. Food and Drug Administration

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.